JP2022527983A - Tuba1cタンパク質を過発現するエクソソーム基盤の癌の診断又は予後予測用マーカー組成物 - Google Patents
Tuba1cタンパク質を過発現するエクソソーム基盤の癌の診断又は予後予測用マーカー組成物 Download PDFInfo
- Publication number
- JP2022527983A JP2022527983A JP2021559019A JP2021559019A JP2022527983A JP 2022527983 A JP2022527983 A JP 2022527983A JP 2021559019 A JP2021559019 A JP 2021559019A JP 2021559019 A JP2021559019 A JP 2021559019A JP 2022527983 A JP2022527983 A JP 2022527983A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- protein
- tuba1c
- exosome
- diagnosing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
5種の肺癌細胞株(H522、A549、H1650、PC9、H1299)、胸腺癌細胞株、及び食道癌細胞株をそれぞれ直径150mmのディッシュで培養した。ここで、超高速遠心分離機を用いて120、000gで4時間の間に遠心分離してエクソソームを除去したFBS(Fetal Bovine Serum)の上層液を培養液として使用した。前記培養液を用いて細胞が70~80%confluency状態になるよう2~3日間連続培養した。
前記実施形態1で選別したGCC2及びTUBA1Cタンパク質を含むエクソソームが肺癌の診断又は予後予測用マーカーとして利用可能性があるか否かを確認するために、正常群(n=3)と肺癌患者群(n=5)の血液で抽出したエクソソームからGCC2及びTUBA1Cの発現レベルをELISA(Enzyme linked immunoassay)分析を通じて確認した。
まず、正常被験者5人、食道癌患者5人の血漿(plasma)試料からエクソソームを抽出した後、TUBA1C ELISA KIT(Mybiosource社のTUBA1C ELISA KIT(Cat No.MBS9336377))を用いて試料内のTUBA1Cタンパク質濃度を確認した。
癌の診断のために、TUBA1C及びGCC2をニ重バイオマーカーとして用いる場合の有用性を評価するために、TUBA1C及びGCC2を単独に使用する場合と、2つのマーカーを併用する場合の診断敏感度変化をROCカーブで確認した。具体的に、正常被験者7名、肺癌患者21人の血漿からエクソソームを抽出した後、GCC2ELISA KIT、TUBA1C ELISA KITを用いてエクソソーム内のGCC2、TUBA1Cタンパク質の濃度を求めた後、統計的にROCカーブを用いてAUC値を確認し、これについて図5に示した。
Claims (11)
- TUBA1C(Tubulin alpha-1C chain)タンパク質の過発現エクソソームを含む、癌の診断又は予後予測用マーカー組成物。
- 前記エクソソームは、GCC2(GRIP and coiled-coil domain-containing protein)タンパク質をさらに含む、請求項1に記載の癌の診断又は予後予測用マーカー組成物。
- 前記癌は、肺癌、胸腺癌又は食道癌である、請求項1又は請求項2に記載の癌の診断又は予後予測用マーカー組成物。
- エクソソーム内のTUBA1C遺伝子に特異的に結合するプライマー又はプローブ、及びエクソソーム内のTUBA1Cタンパク質に特異的に結合する抗体のいずれか1つ以上を含む、癌の診断又は予後予測用組成物。
- 前記組成物は、エクソソーム内のGCC2遺伝子に特異的に結合するプライマー又はプローブ、及びエクソソーム内のGCC2タンパク質に特異的に結合する抗体のいずれか1つ以上をさらに含む、請求項4に記載の癌の診断又は予後予測用組成物。
- 前記癌は、肺癌、胸腺癌又は食道癌である、請求項4又は請求項5に記載の癌の診断又は予後予測用組成物。
- 請求項4又は請求項5に記載の組成物を含む、癌の診断又は予後予測用キット。
- 前記キットは、RT-PCRキット、マイクロアレイチップキット、DNAキット、及びタンパク質チップキットからなる群より選択される1つ以上である、請求項7に記載の癌の診断又は予後予測用キット。
- 生物学的試料から分離したエクソソーム内のTUBA1C遺伝子又はタンパク質の発現レベルを測定するステップを含む、癌の診断又は予後予測に必要な情報を提供する方法。
- 前記エクソソーム内のGCC2遺伝子又はタンパク質の発現レベルを測定するステップをさらに含む、請求項9に記載の癌の診断又は予後予測に必要な情報を提供する方法。
- 前記生物学的試料は、全血、血清、血漿、唾液、尿、喀痰、リンパ液、及び細胞からなる群より選択される1つ以上である、請求項9又は請求項10に記載の癌の診断又は予後予測に必要な情報を提供する方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190039052 | 2019-04-03 | ||
KR10-2019-0039052 | 2019-04-03 | ||
KR1020200040887A KR102350603B1 (ko) | 2019-04-03 | 2020-04-03 | Tuba1c 단백질을 과발현하는 엑소좀 기반 암 진단 또는 예후 예측용 마커 조성물 |
KR10-2020-0040887 | 2020-04-03 | ||
PCT/KR2020/004589 WO2020204665A1 (ko) | 2019-04-03 | 2020-04-03 | Tuba1c 단백질을 과발현하는 엑소좀 기반 암 진단 또는 예후 예측용 마커 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022527983A true JP2022527983A (ja) | 2022-06-07 |
JP7222117B2 JP7222117B2 (ja) | 2023-02-14 |
Family
ID=72667164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021559019A Active JP7222117B2 (ja) | 2019-04-03 | 2020-04-03 | Tuba1cタンパク質を過発現するエクソソーム基盤の癌の診断又は予後予測用マーカー組成物 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20220154283A1 (ja) |
JP (1) | JP7222117B2 (ja) |
WO (1) | WO2020204665A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190093172A1 (en) * | 2016-04-15 | 2019-03-28 | Exosome Diagnostics, Inc. | Plasma-based detection of anaplastic lymphoma kinase (alk) nucleic acids and alk fusion transcripts and uses thereof in diagnosis and treatment of cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100643046B1 (ko) * | 2003-06-12 | 2006-11-10 | 한국생명공학연구원 | 위암 특이적 유전자들의 발현정도 측정을 통한 위암 진단키트 |
CA2795776A1 (en) * | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
WO2012135844A2 (en) * | 2011-04-01 | 2012-10-04 | Cornell University | Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers |
KR20160133740A (ko) * | 2015-05-13 | 2016-11-23 | 경북대학교 산학협력단 | 파이브로넥틴 단백질 양성 엑소좀을 포함하는 암 진단 또는 예후 예측용 조성물 |
KR101750411B1 (ko) * | 2015-07-10 | 2017-06-27 | 한국생명공학연구원 | 엑소좀 단백질 eif3a 특이반응 오토항체검출용 항원 조성물 및 이를 이용한 간암진단법 |
-
2020
- 2020-04-03 JP JP2021559019A patent/JP7222117B2/ja active Active
- 2020-04-03 WO PCT/KR2020/004589 patent/WO2020204665A1/ko active Application Filing
- 2020-04-03 US US17/442,012 patent/US20220154283A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190093172A1 (en) * | 2016-04-15 | 2019-03-28 | Exosome Diagnostics, Inc. | Plasma-based detection of anaplastic lymphoma kinase (alk) nucleic acids and alk fusion transcripts and uses thereof in diagnosis and treatment of cancer |
Non-Patent Citations (1)
Title |
---|
STEPHANIE N HURWITZ ET AL: "Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-s", ONCOTARGET, vol. 7, no. 52, JPN7022004676, 24 November 2016 (2016-11-24), pages 86999 - 87015, ISSN: 0004890093 * |
Also Published As
Publication number | Publication date |
---|---|
WO2020204665A1 (ko) | 2020-10-08 |
US20220154283A1 (en) | 2022-05-19 |
JP7222117B2 (ja) | 2023-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012506253A (ja) | 大腸癌関連マーカーを用いた大腸癌の診断キット、及びそれを用いた大腸癌の診断方法 | |
JP6908785B2 (ja) | Gcc2遺伝子又はタンパク質を過発現するエクソソーム基盤肺癌診断又は予後予測用マーカー組成物 | |
EP3839513A1 (en) | Use of dna-transcription factor complexes for cancer detection | |
US20150338412A1 (en) | Composition for diagnosis of lung cancer and diagnosis kit for lung cancer | |
KR101995189B1 (ko) | 비침습적 체외진단을 위한 간암 진단용 바이오마커 조성물 및 이를 포함하는 키트 | |
JP7222117B2 (ja) | Tuba1cタンパク質を過発現するエクソソーム基盤の癌の診断又は予後予測用マーカー組成物 | |
KR102499664B1 (ko) | 암의 진단용 조성물 | |
JP7432578B2 (ja) | がんマーカーおよびその用途 | |
EP4043881A1 (en) | Cancer test method | |
KR102350603B1 (ko) | Tuba1c 단백질을 과발현하는 엑소좀 기반 암 진단 또는 예후 예측용 마커 조성물 | |
EP2772759B1 (en) | Composition for diagnosis of lung cancer | |
JP2021019612A (ja) | 治療剤に対する抵抗性の診断に使用するためのERCC1アイソフォーム3のmRNAおよび/またはタンパク質ならびにこのmRNAおよび/またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法 | |
KR20130040294A (ko) | 소세포폐암 진단용 조성물 및 소세포폐암 진단키트 | |
KR20200025706A (ko) | Fgf 21을 포함하는 갑상선 암 진단 또는 갑상선 암 예후 예측용 바이오마커 조성물 | |
KR102499678B1 (ko) | 암의 진단용 조성물 | |
US20230145939A1 (en) | Marker composition for cancer diagnosis or prognosis based on exosome overexressing gcc2 | |
KR102325742B1 (ko) | 암의 진단용 조성물 | |
US20230045066A1 (en) | Biomarkers for diagnosing breast cancer and uses thereof | |
KR102280672B1 (ko) | 암의 진단용 조성물 | |
US20090253138A1 (en) | Kif20a directed diagnostics for neoplastic disease | |
US20090233293A1 (en) | Ttk directed diagnostics for neoplastic disease | |
KR20230030228A (ko) | 암의 진단용 조성물 | |
US20090233294A1 (en) | Uhrf1 directed diagnostics for neoplastic disease | |
KR101403019B1 (ko) | 폐암 진단용 마커 | |
CN117677715A (zh) | 一种骨髓瘤生物标志物serpinf2及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211001 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220922 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221004 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221227 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230117 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230202 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7222117 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |